Merck is celebrating its anniversary by conducting 350 charitable activities in around 60 countries

MerckMerck, a leading science and technology ­company, is celebrating its anniversary by conducting 350 charitable activities in around 60 countries. Taking responsibility has always been an integral part of the entrepreneurial approach of Merck and is one of its six values. On the occasion of its 350th anniversary, the company will further intensify its social engagement activities together with its employees.

"We have a long tradition of responsibility, it’s more than just lip service. That's why we want to share the great joy of our anniversary not only with our employees, but also with our local communities," said Walter Galinat, member of the Executive Board of Merck and responsible for the 350th anniversary celebrations. "We take on responsibility for society all over the world. Many of our employees and subsidiaries are involved in this effort, for instance through donations, collaborations with reliable partners and voluntary initiatives," he added.

The activities planned to take place throughout 2018 will focus on health as well as on education and culture. Here, Merck will leverage its 350 years of experience and curiosity, as well as its knowledge and expertise in the areas of health, science and technology. In addition to these efforts, the company also supports a wide array of charitable and environmental initiatives in the communities near its sites and provides disaster relief. The aim is to address challenges facing society, from fighting serious diseases and protecting natural resources to promoting aspiring young scientists.

The projects in the focus area of health are centered around developing local healthcare infrastructure, providing vocational and advanced training to medical staff and raising awareness of health issues. Founded in 2017, for instance, the Merck Foundation supports initiatives to improve the treatment of cancer patients in Africa. And in Guatemala, Merck is working with an organization that provides free healthcare to underprivileged communities and helps people with disabilities.

Within the focus area of education, particular emphasis is placed on sparking young people's interest in science. A prime example is the SPARK volunteer program, under which employees conduct scientific experiments with school children in an effort to arouse their curiosity. A large number of activities are also taking place in Darmstadt, where the company is headquartered. These include an exciting experiment afternoon for school students to mark the tenth anniversary of the Junior Laboratory at the Technical University of Darmstadt. In Indonesia, Merck is supporting the charitable organization Nara Kreatif, with which it is collaborating on environmental and educational projects. These include a school for 300 children in need, at which Merck employees are also volunteering.

Within the focus area of culture, Merck is often engaged in projects that transcend cultural borders, such as a literature initiative in Korea that encourages exchange between Germany and several Asian countries.

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. The company holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

Chemists characterize the fatal fungus among us

Life-threatening fungal infections affect more than two million people worldwide. Effective antifungal medications are very limited. Until now, one of the major challenge...

FDA approves first cancer drug through new oncolog…

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopa...

Discovery of kidney cancer driver could lead to ne…

University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic...

The immune system: T cells are built for speed

Without T cells, we could not survive. They are a key component of our immune system and have highly sensitive receptors on their surface that can detect pathogens. The e...

FDA approves first targeted treatment for patients…

The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (...

Women and older people under-represented in drug t…

Trying to determine how best to treat a patient, doctors often look to randomized clinical trials to guide their choice of what drug to prescribe. One of the most common ...

Novartis renews drug donation of Egaten® (triclabe…

Novartis reaffirms its commitment to the fight against liver fluke (fascioliasis), signing a renewed memorandum of understanding with the World Health Organization (WHO) ...

Pfizer initiates pivotal Phase 3 program for inves…

Pfizer Inc. (NYSE:PFE) and Spark Therapeutics (NASDAQ:ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study (NCT03587116) to evalu...

Sanofi and REVOLUTION Medicines launch global part…

Sanofi and REVOLUTION Medicines, Inc. today announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cell...

Novartis marks a new era for migraine patients wit…

Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days p...

FDA grants Breakthrough Therapy Designation for Ro…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) i...

New findings suggest allergic responses may protec…

The components of the immune system that trigger allergic reactions may also help protect the skin against cancer, suggest new findings. The research, led by Imperial Col...